|
Acanthosis Nigricans
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
|
Neurogenic Urinary Bladder
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
|
Dysarthria
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
|
Photophobia
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
|
Dry skin
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
|
Reduced visual acuity
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
|
Pallor of optic disc
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
|
Dry Skin, CTCAE
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
|
Adrenoleukodystrophy
|
0.030 |
Biomarker
|
disease |
BEFREE |
In this study, we investigated the kinetic characteristics of ELOVL1 using X-ALD fibroblasts and microsomal fractions from ELOVL1 over-expressing HEK293 cell lines and analyzed the inhibition kinetics of a series of fibrates.
|
25499606 |
2015 |
|
Adrenoleukodystrophy
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
Given the likely pathogenic effects of high C26:0 levels, our findings highlight the potential of modulating ELOVL1 activity in the treatment of X-ALD.
|
20166112 |
2010 |
|
Adrenoleukodystrophy
|
0.030 |
Biomarker
|
disease |
BEFREE |
Furthermore, we pay special attention to the role of the VLCFA elongation system in VLCFA homeostasis, with elongation of very long-chain fatty acids like-1 (ELOVL1) as key player, and its relevance to X-ALD.
|
20626744 |
2010 |
|
Dermatitis
|
0.010 |
Biomarker
|
disease |
BEFREE |
The mRNA expression of ELOVL1 and ELOVL4 significantly decreased in AD-like dermatitis, whereas ELOVL1 increased in psoriasis-like dermatitis.
|
30838224 |
2019 |
|
Dry Eye Syndromes
|
0.010 |
Biomarker
|
disease |
BEFREE |
Very long-chain tear film lipids produced by fatty acid elongase ELOVL1 prevent dry eye disease in mice.
|
29401594 |
2018 |
|
Hyperglycemia
|
0.010 |
Biomarker
|
disease |
BEFREE |
Clozapine caused robust reductions in hepatic ceramide and sphingolipid levels (p < 0.0001), upregulated CerS2 (p < 0.05) and ELOVL1 (+ 37%) and induced significant hyperglycemia (vs controls).
|
29720183 |
2018 |
|
Dryness of eye
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Very long-chain tear film lipids produced by fatty acid elongase ELOVL1 prevent dry eye disease in mice.
|
29401594 |
2018 |
|
Neoplasms
|
0.010 |
Biomarker
|
group |
BEFREE |
Furthermore, the TN tumors exhibited stronger ELOVL1 and 6 staining than the EP+H- tumors.
|
28851309 |
2017 |
|
Adrenomyeloneuropathy
|
0.010 |
Biomarker
|
disease |
BEFREE |
This study indicates that miR-196a participated in differential regulation of ELOVL1 and inflammatory response between cALD as compared to AMN and may be a possible biomarker to differentiate between cALD and AMN.
|
26843114 |
2017 |
|
Triple Negative Breast Neoplasms
|
0.010 |
Biomarker
|
disease |
BEFREE |
Marked differences in fatty acid metabolism pathways, including those related to ELOVL1 and 6, were detected between TN and EP+H-, and it was suggested that ELOVL1 and 6-related fatty acid metabolism pathways may be targets for therapies against TN.
|
28851309 |
2017 |
|
Triple-Negative Breast Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Marked differences in fatty acid metabolism pathways, including those related to ELOVL1 and 6, were detected between TN and EP+H-, and it was suggested that ELOVL1 and 6-related fatty acid metabolism pathways may be targets for therapies against TN.
|
28851309 |
2017 |
|
Protein Deficiency
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
ABCD1 protein deficiency impairs peroxisomal very long-chain fatty acid (VLCFA) degradation resulting in increased cytosolic VLCFA-CoA levels, which are further elongated by the VLCFA-specific elongase, ELOVL1.
|
25499606 |
2015 |